Title:Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in
Traumatic Brain Injury (TBI)
Volume: 23
Issue: 11
Author(s): Sumel Ashique*, Radheshyam Pal, Himanshu Sharma, Neeraj Mishra and Ashish Garg
Affiliation:
- Department of Pharmaceutical Science, Pandaveswar School of Pharmacy, Pandaveswar, West Bengal 713378,
India
Keywords:
Traumatic brain injury, exosome, extracellular vesicles, brain, biomarker, clinical trials.
Abstract: Extracellular vesicles or exosomes, often known as EVs, have acquired significant attention
in the investigations of traumatic brain injury (TBI) and have a distinct advantage in actively
researching the fundamental mechanisms underlying various clinical symptoms and diagnosing the
wide range of traumatic brain injury cases. The mesenchymal stem cells (MSCs) can produce and
release exosomes, which offer therapeutic benefits. Exosomes are tiny membranous vesicles produced
by various cellular entities originating from endosomes. Several studies have reported that
administering MSC-derived exosomes through intravenous infusions improves neurological recovery
and promotes neuroplasticity in rats with traumatic brain damage. The therapeutic advantages of
exosomes can be attributed to the microRNAs (miRNAs), which are small non-coding regulatory
RNAs that significantly impact the regulation of posttranscriptional genes. Exosome-based therapies,
which do not involve cells, have lately gained interest as a potential breakthrough in enhancing
neuroplasticity and accelerating neurological recovery for various brain injuries and neurodegenerative
diseases. This article explores the benefits and drawbacks of exosome treatment for traumatic
brain injury while emphasizing the latest advancements in this field with clinical significance.